Brain metastases
- PMID: 15102346
- DOI: 10.1007/s11910-004-0040-6
Brain metastases
Abstract
Despite advances in the treatment of cancer, brain metastases appear to be increasing in frequency and are associated with a poor prognosis. Type of tumor, age, performance status, and extent of systemic disease are important prognostic factors that should be taken into consideration when making treatment decisions. Patients with a good performance status and controlled systemic disease may benefit from aggressive focal therapies (surgery or radiosurgery). Whole brain radiotherapy seems to increase local control but is associated with the risk of delayed cognitive deterioration in long-term survivors. In spite of this, whole brain radiotherapy remains the standard of care for those patients with poorer prognosis and for the treatment of recurrence after focal therapy. Chemotherapy has a limited role in the treatment of brain metastases but should be considered in selected patient populations.
Similar articles
-
Management of brain metastases.J Neurol. 2002 Oct;249(10):1357-69. doi: 10.1007/s00415-002-0870-6. J Neurol. 2002. PMID: 12382150 Review.
-
Surgical therapies in brain metastasis.Semin Oncol. 2007 Jun;34(3):197-205. doi: 10.1053/j.seminoncol.2007.03.011. Semin Oncol. 2007. PMID: 17560981 Review.
-
Current treatment paradigms for the management of patients with brain metastases.Neurosurgery. 2005 Nov;57(5 Suppl):S66-77; discusssion S1-4. doi: 10.1227/01.neu.0000182739.84734.6e. Neurosurgery. 2005. PMID: 16237291 Review.
-
Treatment of brain metastases.Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Dec;160(4):484-490. doi: 10.5507/bp.2016.058. Epub 2016 Nov 23. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016. PMID: 27876898 Review.
-
Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):303-9. doi: 10.1016/j.ijrobp.2011.06.1987. Epub 2011 Nov 11. Int J Radiat Oncol Biol Phys. 2012. PMID: 22079723
Cited by
-
Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis.Open Med (Wars). 2023 Feb 14;18(1):20220574. doi: 10.1515/med-2022-0574. eCollection 2023. Open Med (Wars). 2023. PMID: 36820064 Free PMC article.
-
Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial.J Neurooncol. 2006 Jul;78(3):277-80. doi: 10.1007/s11060-005-9095-8. Epub 2006 Apr 14. J Neurooncol. 2006. PMID: 16614943 Clinical Trial.
-
Metastatic disease of the brain: extra-axial metastases (skull, dura, leptomeningeal) and tumour spread.Eur Radiol. 2005 Mar;15(3):617-26. doi: 10.1007/s00330-004-2617-5. Epub 2004 Dec 31. Eur Radiol. 2005. PMID: 15627175 Review.
-
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases.J Neurooncol. 2008 Mar;87(1):85-90. doi: 10.1007/s11060-007-9491-3. Epub 2007 Nov 7. J Neurooncol. 2008. PMID: 17987262 Clinical Trial.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical